{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:21:05Z","timestamp":1790216465316,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,23]]},"DOI":"10.7759\/cureus.15852","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:31:53Z","timestamp":1624444313000},"source":"Crossref","is-referenced-by-count":2,"title":["Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?"],"prefix":"10.7759","author":[{"given":"Sezin","family":"Yuce Sari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak Yasin","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neyran","family":"Kertmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysenur","family":"Elmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kader","family":"Karli Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Mut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Figen","family":"Soylemezoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"Zorlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA2000","article-title":"Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q co-deletion: an intergroup trial","volume":"34","author":"Van den Bent MJ","year":"2016","unstructured":"Van den Bent MJ, Erridge S, Vogelbaum MA, et al.. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q co-deletion: an intergroup trial. J Clin Oncol. 2016, 34:LBA2000. 10.1200\/JCO.2016.34.18_suppl.LBA2000","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert MR","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, et al.. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014, 370:699-708. 10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot OL","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, et al.. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014, 370:709-22. 10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_538_2020","article-title":"Reoperation for recurrent glioblastomas: what to expect?","volume":"12","author":"Neville IS","year":"2021","unstructured":"Neville IS, Dos Santos AG, Almeida CC, et al.. Reoperation for recurrent glioblastomas: what to expect?. Surg Neurol Int. 2021, 12:42. 10.25259\/SNI_538_2020","journal-title":"Surg Neurol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas","volume":"28","author":"Fogh SE","year":"2010","unstructured":"Fogh SE, Andrews DW, Glass J, et al.. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010, 28:3048-53. 10.1200\/JCO.2009.25.6941","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4157","article-title":"Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution","volume":"23","author":"Combs SE","year":"2005","unstructured":"Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005, 23:8863-9. 10.1200\/JCO.2005.03.4157","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1524-0","article-title":"Hypofractionated stereotactic reirradiation for recurrent glioblastoma","volume":"120","author":"Yazici G","year":"2014","unstructured":"Yazici G, Cengiz M, Ozyigit G, et al.. Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol. 2014, 120:117-23. 10.1007\/s11060-014-1524-0","journal-title":"J Neurooncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101764","article-title":"Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model","volume":"9","author":"Belcaid Z","year":"2014","unstructured":"Belcaid Z, Phallen JA, Zeng J, et al.. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One. 2014, 9:e101764. 10.1371\/journal.pone.0101764","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam S","year":"2021","unstructured":"Sahebjam S, Forsyth PA, Tran ND, et al.. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neuro Oncol. 2021, 23:677-86. 10.1093\/neuonc\/noaa260","journal-title":"Neuro Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnci.2016.07.001","article-title":"Management of glioblastoma after recurrence: a changing paradigm","volume":"28","author":"Mallick S","year":"2016","unstructured":"Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after recurrence: a changing paradigm. J Egypt Natl Canc Inst. 2016, 28:199-210. 10.1016\/j.jnci.2016.07.001","journal-title":"J Egypt Natl Canc Inst"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen PY","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, et al.. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010, 28:1963-72. 10.1200\/JCO.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada H","year":"2015","unstructured":"Okada H, Weller M, Huang R, et al.. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015, 16:e534-42. 10.1016\/S1470-2045(15)00088-1","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al.. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016, 131:803-20. 10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2466-0","article-title":"Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series","volume":"133","author":"Chamberlain MC","year":"2017","unstructured":"Chamberlain MC, Kim BT. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol. 2017, 133:561-9. 10.1007\/s11060-017-2466-0","journal-title":"J Neurooncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon DA","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, et al.. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1003-10. 10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng J","year":"2013","unstructured":"Zeng J, See AP, Phallen J, et al.. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013, 86:343-9. 10.1016\/j.ijrobp.2012.12.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28499","article-title":"Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression","volume":"3","author":"Deng L","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Weicheslbaum RR, Fu YX. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology. 2014, 3:e28499. 10.4161\/onci.28499","journal-title":"Oncoimmunology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor C","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, et al.. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015, 520:373-7. 10.1038\/nature14292","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade AA","year":"2008","unstructured":"Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008, 180:3132-9. 10.4049\/jimmunol.180.5.3132","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits EA","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, et al.. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006, 203:1259-71. 10.1084\/jem.20052494","journal-title":"J Exp Med"},{"key":"ref22","article-title":"Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review)","volume":"9","author":"van Vulpen M","year":"2002","unstructured":"van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002, 9:683-8.","journal-title":"Oncol Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang C","year":"2014","unstructured":"Tang C, Liao Z, Gomez D, et al.. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014, 89:1084-91. 10.1016\/j.ijrobp.2014.04.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan J","year":"2018","unstructured":"Lan J, Li R, Yin LM, et al.. Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy. Int J Radiat Oncol Biol Phys. 2018, 101:74-87. 10.1016\/j.ijrobp.2018.01.071","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin M","year":"2019","unstructured":"Grapin M, Richard C, Limagne E, et al.. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019, 7:160. 10.1186\/s40425-019-0634-9","journal-title":"J Immunother Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi AB","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015, 16:498-509. 10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-48. 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq169","article-title":"Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?","volume":"13","author":"Heimberger AB","year":"2011","unstructured":"Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Neuro Oncol. 2011, 13:3-13. 10.1093\/neuonc\/noq169","journal-title":"Neuro Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi SJ","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al.. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014, 74:5458-68. 10.1158\/0008-5472.CAN-14-1258","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia SJ","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al.. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017, 377:1919-29. 10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/59536-does-combined-fractionated-stereotactic-radiotherapy-and-immunotherapy-change-the-outcome-of-recurrent-high-grade-gliomas","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:05Z","timestamp":1707506705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/59536-does-combined-fractionated-stereotactic-radiotherapy-and-immunotherapy-change-the-outcome-of-recurrent-high-grade-gliomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.15852","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}